Due to recent changes in the official account's push mechanism, we welcome you to set Boom Health as a “Star” on the homepage of our official account to receive the latest trends and expert insights in the digital healthcare industry at the earliest opportunity!
01 Overview of Global Digital Health Investment and FinancingRepeatMD, a SaaS Platform Provider for Aesthetics and Wellness, Secures $50 Million in Series A FundingOn November 27, RepeatMD, a SaaS platform provider for the aesthetics and wellness sectors, secured $50 million in Series A financing. The round was co-led by Centana Growth Partners and Full In Partners, with participation from PROOF, and included a $10 million debt facility from Silicon Valley Bank. The company helps aesthetics and wellness practices grow their businesses through an automated revenue-generating inbound patient platform, providing software solutions to numerous medical, aesthetics, and wellness organizations.Brain-Computer Interface Developer Neuralink Secures $43 Million in FundingOn November 25, brain-computer interface company Neuralink secured $43 million in venture capital, led by Founders Fund, the venture capital fund of Silicon Valley legendary investor Peter Thiel. Thirty-two investors participated in this financing round, bringing the total size of the latest funding round from $280 million in August to $323 million.Protein Therapy Developer Aro Biotherapeutics Secures $41.5 Million in Series B FundingOn November 28, protein therapy developer Aro Biotherapeutics secured $41.5 million in Series B financing, led by Cowen Healthcare Investments. The company is a pioneer in developing tissue-targeted genetic medicines, leveraging its proprietary Centyrins protein technology platform. The funds will be used to advance the development of ABX1100, a novel potential therapy for patients with Pompe disease, as well as its new therapeutic program for autoimmune diseases, Centyrin-siRNA.Aidoc, an AI-powered medical imaging diagnostic analysis service provider, secures $30 million in fundingOn November 28, Aidoc, an AI-powered medical imaging diagnosis and analysis service provider, announced that it had secured $30 million in funding to develop comprehensive artificial intelligence imaging models and new product categories based on these models. Aidoc provides radiologists with tools for assessing injuries and health conditions, offers coordination software for stroke and cardiovascular care, and delivers AI multimodal training infrastructure along with its AI-driven clinical workflow operating system, aIOS.Protein Design and Programming Platform Cradle Secures $24 Million in Series A FundingOn November 28, Cradle, a protein design and programming platform, secured $24 million in Series A financing, led by Index Ventures with participation from Kindred Capital. The funds will be used to accelerate growth, expand its machine learning and biotechnology teams, and continue investing in product development and sales capabilities. Cradle leverages generative AI to help scientists design and manufacture proteins, utilizing powerful predictive algorithms and AI-driven design recommendations.Med-FinTech Payment Platform PayGround Completes $19.7 Million Series A FinancingOn November 29, PayGround, a medical fintech payment platform, announced the completion of an oversubscribed $19.7 million Series A financing round, led by SixThirty with participation from Rally Ventures, IA Capital Group, FCA Venture Partners, and Plug and Play Ventures. The funding will enable the company to rapidly expand into hospitals and health systems, building on its success in the outpatient market, and to strengthen its senior leadership team.Cannabis AI Supply Chain Solutions Provider Prelude Completes $5.2 Million Seed Funding RoundOn November 28, Prelude, an AI-powered supply chain solutions provider for the cannabis industry, completed a $5.2 million seed funding round co-led by Rackhouse Ventures and Casa Verde. Prelude Products operates a supply chain platform for cannabis retail, aiming to align inventory with customer demand and help cannabis dispensaries reduce stockouts and overstock situations.AI-Driven Medical Device Developer Boshikang Secures Tens of Millions in Series A FundingOn November 30, BoshiKang, a developer of digital and intelligent medical equipment, secured tens of millions of yuan in Series A financing, jointly invested by Zhongxi Life and Dachuang Ruifeng. The funds from this round will be used for the market promotion of the company’s core product, the sub-millimeter high-precision “Optical-Magnetic Integrated Spinal Surgery Navigation System,” as well as for the research and development of subsequent new products, thereby driving BoshiKang’s continuous growth in the field of precise minimally invasive surgery.Shengzhi Medical, Developer of Minimally Invasive Treatment Technologies, Completes Tens of Millions of Yuan in Pre-A FinancingOn November 29, Shengzhi Medical, a developer of minimally invasive treatment technologies, completed a Pre-A financing round worth tens of millions of yuan, led by Haimaide Venture Capital, with continued increased investment from existing shareholder Fengyu Capital. Shengzhi Medical specializes in surgical minimally invasive treatments and is committed to building an innovative ecosystem for tumor treatment via laparoscopic, endoscopic, and percutaneous approaches, leveraging its proprietary "Me Better" technologies based on multi-degree-of-freedom mechanical control, novel energy sources, and digitalization.Tumor Treating Fields Developer Saifu Kai'er Completes Tens of Millions of Yuan in Pre-A Financing RoundOn November 27, Saifu Kai'er completed a Pre-A financing round of tens of millions of yuan, led by Puhua Capital. The funds will be used to continuously develop product technologies, conduct human clinical trials around the multiple "Tumor Treating Fields (TTF+)" pipelines accumulated in the early stage, and the team is also actively engaging with domestic industrialization partners to jointly explore the application of electric field technology and promote its commercial implementation.Qijia Technology, Developer of Bionic Micro-Organ Platform, Completes Tens of Millions of Yuan in Angel FinancingOn November 27, Qijia Technology completed an angel financing round worth tens of millions of yuan, exclusively led by iFlytek Venture Capital, with Probe Capital serving as the exclusive financial advisor. The funds raised will be used for the development and commercial translation of a human biomimetic micro-organ technology platform. Currently, Qijia has completed the development of a human-derived respiratory and digestive tract biomimetic micro-organ system, offering standardized products and customized services for biomimetic micro-organs such as human lungs, livers, pancreas, duodenum, and colorectal tissues.Healthy Sleep Management Platform Keshuimao Secures Strategic FundingOn November 27, Keshuimao, a health sleep management platform, received strategic investment from Longling Capital, reaching a post-investment valuation of 130 million. The funds from this round of financing will be used for the research and development of sleep product lines and market expansion. The company plans to introduce more institutional investors within five years and intends to list on the main board of the Hong Kong Stock Exchange.SafeRide Health, a Non-Emergency Medical Transportation Network Optimization Platform, Secures Strategic FundingOn November 27, SafeRide Health, a leading non-emergency medical transportation (NEMT) network optimization platform, secured strategic financing from SEMCAP Health. The funding will support the company’s continued platform development and expansion of its customer base among Medicaid and Medicare Advantage health plans.02 Digital Health Industry Updates
Genentech Collaborates with NVIDIAOn November 22, Genentech, a member of the Roche Group, announced a multi-year strategic research collaboration with NVIDIA. This partnership combines Genentech’s expertise in artificial intelligence (AI), extensive biological and molecular data, and R&D capabilities with NVIDIA’s leading technologies in accelerated computing and AI to accelerate the drug discovery and development process. The goal is to significantly advance Genentech’s cutting-edge AI research initiatives by upgrading its generative AI models and algorithms into an advanced AI platform, thereby speeding up the arrival of innovative therapies.BeiGene and Ensem Therapeutics Enter into Licensing Collaboration AgreementOn November 21, BeiGene secured exclusive global licensing rights to an investigational oral cyclin-dependent kinase 2 (CDK2) inhibitor from OncoTherapy, which is poised to submit an Investigational New Drug (IND) application. Under the terms of the agreement, OncoTherapy will receive an upfront payment and is eligible for potential total payments of up to $1.33 billion, contingent upon the achievement of specified development, regulatory, and commercialization milestones.Yousen Jianheng and AstraZeneca Reach Global Exclusive Licensing AgreementOn November 20, Yousen Jianheng and AstraZeneca reached a global exclusive licensing agreement for the preclinical-stage small-molecule candidate drug UA022, which targets the KRAS G12D mutation. Under the terms of the agreement, AstraZeneca will obtain the global exclusive license to research, develop, and commercialize UA022. Yousen Jianheng will be eligible to receive an upfront payment of $24 million, as well as potential development and commercialization milestones totaling up to $395 million.03 Overview of Global Digital Health M&AZhifei Biological Products Plans to Acquire 100% Equity Interest in Chen'an BiologicalOn November 23, Zhifei Biological Products proposed to acquire 100% equity of Chongqing Chen'an Biopharmaceutical Co., Ltd. in cash. Chen'an Biopharmaceutical focuses on metabolic diseases such as diabetes and obesity, and has established a tiered pipeline layout of GLP-1 analogs and insulin analogs.CNNC Health Acquires Northern Institute, a Wholly-Owned Subsidiary of China Isotope & RadiationOn November 23, China Isotope & Radiation Corporation announced the sale of its 100% equity interest in Northern Institute (Beijing Northern Biotechnology Research Institute Co., Ltd.) to CNNC Health for a purchase price of RMB 260 million. Northern Institute is a wholly-owned subsidiary of China Isotope & Radiation Corporation’s in vitro diagnostics business segment and has been deeply engaged in the field of radioimmunoassay for nearly 40 years.Microline Surgical Acquires Retraction Assets for Laparoscopic Surgical InstrumentsOn November 21, Microline Surgical, a subsidiary of HOYA Corporation, announced that it had acquired certain laparoscopic surgical instrument assets from RETRACTION Limited. With over 30 years of expertise in the field of laparoscopic instruments and an extensive product portfolio, Microline Surgical will further enhance its presence in this sector and solidify its market position through this acquisition.VCBeat/Arterial Orange Industry Think Tank/China Renaissance / BGI Win-Win / Rock Health / Mobile Health News / Fierce Health, etc.
Compiled by: Zhang Qiankun
